Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel MYO5C-ALK fusion in lung adenocarcinoma: limited alectinib response and durable lorlatinib benefit.

Lung cancer (Amsterdam, Netherlands) - 1 Sept 2026

Wu Tai-Yun, Liu Nien-Tzu, Wu Yu-Cheng, Liu Chia-Hsin

Abstract excerpt

OBJECTIVES: Anaplastic lymphoma kinase (ALK) rearrangements drive approximately 5% of non-small cell lung cancers (NSCLC), most commonly as EML4-ALK, but rare 5' partners may confer distinct pharmacologic behaviour. We report the first lung adenocarcinoma harbouring a novel MYO5C (exon 23)-ALK (exon 20) fusion. MATERIALS AND METHODS: Diagnosis and resistance profiling used DNA- and RNA-based next-generation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Anaplastic Lymphoma Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbazoles

Share to Lactams

Share to Lactams, Macrocyclic

Share to Oncogene Proteins, Fusion

Share to Piperidines

Share to Pyrazoles

Source

Identifiers

PMID: 42485678
DOI: 10.1016/j.lungcan.2026.109548

Genes

ALK
MYO5C
EML4
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

A novel MYO5C-ALK fusion in lung adenocarcinoma: limited alectinib response and durable lorlatinib benefit.PMID 42485678Read ↗

Molecular tumor board: molecularly adjusted therapy upon identification and functional validation of a novel ALK resistance mutation in a case of lung adenocarcinoma.Semantic proximity Read ↗

Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib.Semantic proximity Read ↗

Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.Semantic proximity Read ↗

A comprehensive functional atlas of ALK kinase domain variants reveals resistance landscape to ALK inhibitors.Semantic proximity Read ↗

Identification of a novel crizotinib-sensitive BCL11A-ALK gene fusion in a nonsmall cell lung cancer patientSemantic proximity Read ↗

EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridge.Semantic proximity Read ↗

ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.Semantic proximity Read ↗

A Novel Linc00308/D21S2088E Intergenic Region ALK Fusion and Its Enduring Clinical Responses to CrizotinibSemantic proximity Read ↗

Cryo-EM structure of human LRRC15 reveals the basis of therapeutic antibody recognitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.